A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors.

Tracy Murray StewartApurva A DesaiMichael L FitzgeraldLaurence J MartonRobert A Casero

Published in: Cancer chemotherapy and pharmacology (2020)

Results of this phase I trial suggest that PG-11047 can be safely administered to patients on the once weekly dosing schedule described. The manageable toxicity profile and high MTD determination provide a safety profile for further clinical studies, including those in combination with current chemotherapeutic agents.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
clinical trial
study protocol
randomized controlled trial
open label
patient reported outcomes
liquid chromatography